AR070467A1 - Inhibidores de quinasa de pirrolopirazina - Google Patents
Inhibidores de quinasa de pirrolopirazinaInfo
- Publication number
- AR070467A1 AR070467A1 ARP090100620A ARP090100620A AR070467A1 AR 070467 A1 AR070467 A1 AR 070467A1 AR P090100620 A ARP090100620 A AR P090100620A AR P090100620 A ARP090100620 A AR P090100620A AR 070467 A1 AR070467 A1 AR 070467A1
- Authority
- AR
- Argentina
- Prior art keywords
- phenyl
- lower alkyl
- haloalkyl
- heterocycloalkyl
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Inhiben la JAK y la SYK y son utiles para el tratamiento de enfermedades inflamatorias y autoinmunes. Reivindicacion 1: Un compuesto de la formula 1 en la que: R es R1, R2, R3 o R4; R1 es alquilo inferior, alcoxi inferior, fenilo, bencilo, heteroarilo, cicloalquilo, heterocicloalquilo o cicloalquilalquilo, opcionalmente sustituido por uno o más R1a; R1a es R1b o R1c; R1b es halogeno, oxo, hidroxi o -CN; R1c es -C(=O)O(R1f), -C(=O)(CH2)m(R1e), -O(CH2)m(R1e), -S(R1f), -S(O)2(R1f) o -S(=O)(R1f), alquilo inferior, alcoxi inferior, amino, amido, haloalquilo inferior, fenilo, heteroarilo, cicloalquilo, heterocicloalquilo, cicloalquiloxi o heterocicloalquiloxi opcionalmente sustituido por uno o más R1d; R1d es H, halogeno, hidroxi, alquilo inferior, amino, alcoxi inferior o haloalquilo inferior; R1e es H, alquilo inferior, alcoxi inferior, ciano, haloalquilo inferior, fenilo, heteroarilo, cicloalquilo o heterocicloalquilo; R1f es H, alquilo inferior, haloalquilo inferior, fenilo, heteroarilo, cicloalquilo o heterocicloalquilo; m es el numero 0, 1 o 2; R2 es N(R2a)2; cada R2a es con independencia H o R2b; cada R2b es con independencia alquilo inferior, fenilo, heteroarilo, cicloalquilo, heterocicloalquilo o heterocicloalquil-alquileno, opcionalmente sustituido por uno o más R2c; R2c es R2d o R2e; R2d es halogeno, oxo o hidroxi; R2e es -N(R2g)2, -C(=O)(R2g), -C(=O)O(R2g), -C(=O)N(R2g)2, -N(R2g)C(=O)(R2g), -S(=O)2(R2g), -S(O)2N(R2g)2, alquilo inferior, alcoxi inferior, haloalquilo inferior, fenilo, heteroarilo, heteroariloxi, cicloalquilo o heterocicloalquilo, opcionalmente sustituido por uno o más R2f; cada R2f es con independencia H, halogeno, alquilo inferior, alcoxi inferior, haloalquilo inferior; cada R2g es con independencia H, alquilo inferior, alcoxi inferior, haloalquilo inferior o fenilo; R3 es -C(=O)R3a; R3a es alquilo inferior, alcoxi inferior, fenilo o N(R3b)2; cada R3b es con independencia H o alquilo inferior; R4 es -O(R4a); R4a es H o R4b; R4b es alquilo inferior, fenilo, bencilo, haloalquilo inferior, cicloalquilo, heterocicloalquilo, heteroarilo, opcionalmente sustituido por uno o más R4c; R4c es halogeno, hidroxi, alquilo inferior, haloalquilo inferior o alcoxi inferior; Q4 es Q4a o Q4b; Q4a es H, hidroxi, ciano o halogeno; Q4b es alquilo inferior, alquenilo inferior, alquinilo inferior, hidroxialquilo inferior, amino o haloalquilo inferior, opcionalmente sustituido por uno o más Q4c; Q4c es Q4d o Q4e; cada Q4d es con independencia halogeno, hidroxi o ciano; cada Q4e es con independencia alquilo inferior, haloalquilo inferior, alcoxi inferior, amino, cicloalquilo, fenilo, heterocicloalquilo o heteroarilo, opcionalmente sustituido por uno o más Q4f; cada Q4f es con independencia hidroxi, halogeno, alquilo inferior, alquenilo inferior, oxo, haloalquilo inferior, alcoxi inferior, hidroxialquilo inferior o amino; con la condicion de que cuando R es R4, R4 es -O(R4a), R4a es H y Q4 es Q4a, entonces Q4a no sea H; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3103508P | 2008-02-25 | 2008-02-25 | |
US14651409P | 2009-01-22 | 2009-01-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR070467A1 true AR070467A1 (es) | 2010-04-07 |
Family
ID=40514045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090100620A AR070467A1 (es) | 2008-02-25 | 2009-02-23 | Inhibidores de quinasa de pirrolopirazina |
Country Status (18)
Country | Link |
---|---|
US (1) | US8119636B2 (es) |
EP (1) | EP2247593B1 (es) |
JP (1) | JP5284377B2 (es) |
KR (1) | KR20100114095A (es) |
CN (1) | CN101952296B (es) |
AR (1) | AR070467A1 (es) |
AT (1) | ATE519763T1 (es) |
AU (1) | AU2009218609A1 (es) |
BR (1) | BRPI0907928A2 (es) |
CA (1) | CA2713718A1 (es) |
CL (1) | CL2009000405A1 (es) |
IL (1) | IL206818A0 (es) |
MX (1) | MX2010009023A (es) |
PE (1) | PE20091738A1 (es) |
RU (1) | RU2010139284A (es) |
TW (1) | TW200942543A (es) |
WO (1) | WO2009106444A1 (es) |
ZA (1) | ZA201004942B (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101945877B (zh) * | 2008-02-25 | 2013-07-03 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪激酶抑制剂 |
PL2250172T3 (pl) * | 2008-02-25 | 2012-01-31 | Hoffmann La Roche | Pirolopirazynowe inhibitory kinazy |
MX2011004953A (es) | 2008-11-10 | 2011-12-14 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa atr. |
CA2747252C (en) | 2008-12-19 | 2018-09-18 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of atr kinase |
US8518945B2 (en) * | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
US8481541B2 (en) | 2010-03-22 | 2013-07-09 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
US9062008B2 (en) | 2010-05-12 | 2015-06-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP2569289A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Pyrazines useful as inhibitors of atr kinase |
CN102947272A (zh) | 2010-05-12 | 2013-02-27 | 沃泰克斯药物股份有限公司 | 用作atr激酶抑制剂的2-氨基吡啶衍生物 |
EP2568984A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
CA2798763A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US9334244B2 (en) | 2010-05-12 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP2571880A1 (en) * | 2010-05-20 | 2013-03-27 | F.Hoffmann-La Roche Ag | Pyrrolo [2, 3 - b]pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors |
JP2013526558A (ja) * | 2010-05-20 | 2013-06-24 | エフ.ホフマン−ラ ロシュ アーゲー | Syk及びjak阻害剤としてのピロロピラジン誘導体 |
CA2803802A1 (en) | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
CN103562204A (zh) | 2011-04-05 | 2014-02-05 | 沃泰克斯药物股份有限公司 | 可用作tra激酶的抑制剂的氨基吡嗪化合物 |
US9187487B2 (en) | 2011-05-17 | 2015-11-17 | Principia Biopharma, Inc. | Azaindole derivatives as tyrosine kinase inhibitors |
WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
JP2014520161A (ja) | 2011-06-22 | 2014-08-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
EP2723747A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
KR20140074912A (ko) * | 2011-09-01 | 2014-06-18 | 에프. 호프만-라 로슈 아게 | 피롤로피라진 키나아제 억제제 |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
AU2012315384B2 (en) | 2011-09-30 | 2017-08-10 | Vertex Pharmaceuticals Incorporated | Treating pancreatic cancer and non-small cell lung cancer with ATR inhibitors |
EP2751088B1 (en) | 2011-09-30 | 2016-04-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US9035053B2 (en) | 2011-09-30 | 2015-05-19 | Vertex Pharmaceuticals Incorporated | Processes for making compounds useful as inhibitors of ATR kinase |
WO2013049722A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2773645A1 (en) | 2011-11-01 | 2014-09-10 | F.Hoffmann-La Roche Ag | Imidazopyridazine compounds |
EP2776429A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
JP2015502925A (ja) | 2011-11-09 | 2015-01-29 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用なピラジン化合物 |
CA2860547A1 (en) | 2012-01-10 | 2013-07-18 | Johannes Cornelius Hermann | Pyridazine amide compounds and their use as syk inhibitors |
LT2833973T (lt) | 2012-04-05 | 2018-02-12 | Vertex Pharmaceuticals Incorporated | Junginiai, tinkami naudoti kaip atr kinazės inhibitoriai, ir jų kombinuotas gydymas |
BR112015002262A2 (pt) * | 2012-08-21 | 2019-12-10 | Hoffmann La Roche | compostos, métodos para os tratamentos de uma condição inflamatória, artrite reumatóide, asma e distúrbio imunológico; composição farmacêutica, utilização do composto e invenção |
EP2904406B1 (en) | 2012-10-04 | 2018-03-21 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
WO2014062604A1 (en) | 2012-10-16 | 2014-04-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
SI2941432T1 (en) | 2012-12-07 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR |
WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
CN105209435B (zh) * | 2013-05-14 | 2018-02-02 | 3M创新有限公司 | 包含吡啶或吡嗪的化合物 |
RU2720408C2 (ru) | 2013-12-06 | 2020-04-29 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения ингибиторов atr киназы (варианты) |
RU2719583C2 (ru) | 2014-06-05 | 2020-04-21 | Вертекс Фармасьютикалз Инкорпорейтед | Радиоактивно меченные производные 2-амино-6-фтор-n-[5-фтор-пиридин-3-ил]-пиразоло[1, 5-а]пиримидин-3-карбоксамида, используемые в качестве ингибитора atr киназы, препараты на основе этого соединения и его различные твердые формы |
CA2950780C (en) | 2014-06-17 | 2023-05-16 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of chk1 and atr inhibitors |
JP7187308B2 (ja) | 2015-09-30 | 2022-12-12 | バーテックス ファーマシューティカルズ インコーポレイテッド | Dna損傷剤とatr阻害剤との組み合わせを使用する、がんを処置するための方法 |
US20170100396A1 (en) | 2015-10-07 | 2017-04-13 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza |
CR20220299A (es) | 2019-12-20 | 2022-08-05 | Pfizer | Derivados de becimidazol |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DZ3377A1 (fr) | 1999-12-24 | 2001-07-05 | Aventis Pharma Ltd | Azaindoles |
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
WO2003082868A1 (en) | 2002-03-28 | 2003-10-09 | Eisai Co., Ltd. | 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders |
PT1696920E (pt) * | 2003-12-19 | 2015-01-14 | Plexxikon Inc | Compostos e métodos para o desenvolvimento de moduladores de ret |
MX2007006103A (es) * | 2004-11-22 | 2007-07-20 | Vertex Pharma | Pirrolopirazinas y pirazolopirazinas de utilidad como inhibidores de proteinquinasas. |
US7456289B2 (en) * | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
CL2007002617A1 (es) | 2006-09-11 | 2008-05-16 | Sanofi Aventis | Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. |
WO2008063888A2 (en) * | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
PL2250172T3 (pl) * | 2008-02-25 | 2012-01-31 | Hoffmann La Roche | Pirolopirazynowe inhibitory kinazy |
MX2010008198A (es) * | 2008-02-25 | 2010-08-23 | Hoffmann La Roche | Inhibidores de cinasa de pirrolopirazina. |
-
2009
- 2009-02-16 EP EP09714560A patent/EP2247593B1/en not_active Not-in-force
- 2009-02-16 RU RU2010139284/04A patent/RU2010139284A/ru unknown
- 2009-02-16 CN CN2009801062407A patent/CN101952296B/zh not_active Expired - Fee Related
- 2009-02-16 CA CA2713718A patent/CA2713718A1/en not_active Abandoned
- 2009-02-16 KR KR1020107018679A patent/KR20100114095A/ko not_active Application Discontinuation
- 2009-02-16 AT AT09714560T patent/ATE519763T1/de not_active IP Right Cessation
- 2009-02-16 WO PCT/EP2009/051759 patent/WO2009106444A1/en active Application Filing
- 2009-02-16 BR BRPI0907928-9A patent/BRPI0907928A2/pt not_active IP Right Cessation
- 2009-02-16 AU AU2009218609A patent/AU2009218609A1/en not_active Abandoned
- 2009-02-16 JP JP2010548070A patent/JP5284377B2/ja not_active Expired - Fee Related
- 2009-02-16 MX MX2010009023A patent/MX2010009023A/es not_active Application Discontinuation
- 2009-02-20 US US12/378,837 patent/US8119636B2/en not_active Expired - Fee Related
- 2009-02-23 AR ARP090100620A patent/AR070467A1/es unknown
- 2009-02-23 CL CL2009000405A patent/CL2009000405A1/es unknown
- 2009-02-23 TW TW098105680A patent/TW200942543A/zh unknown
- 2009-02-23 PE PE2009000261A patent/PE20091738A1/es not_active Application Discontinuation
-
2010
- 2010-07-05 IL IL206818A patent/IL206818A0/en unknown
- 2010-07-13 ZA ZA2010/04942A patent/ZA201004942B/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2010009023A (es) | 2010-09-07 |
JP2011513263A (ja) | 2011-04-28 |
JP5284377B2 (ja) | 2013-09-11 |
ZA201004942B (en) | 2011-12-28 |
WO2009106444A1 (en) | 2009-09-03 |
ATE519763T1 (de) | 2011-08-15 |
PE20091738A1 (es) | 2009-11-13 |
IL206818A0 (en) | 2010-12-30 |
CN101952296B (zh) | 2013-08-21 |
EP2247593A1 (en) | 2010-11-10 |
US8119636B2 (en) | 2012-02-21 |
CA2713718A1 (en) | 2009-09-03 |
CL2009000405A1 (es) | 2010-02-26 |
AU2009218609A1 (en) | 2009-09-03 |
EP2247593B1 (en) | 2011-08-10 |
KR20100114095A (ko) | 2010-10-22 |
TW200942543A (en) | 2009-10-16 |
CN101952296A (zh) | 2011-01-19 |
US20090215785A1 (en) | 2009-08-27 |
BRPI0907928A2 (pt) | 2015-07-28 |
RU2010139284A (ru) | 2012-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR070467A1 (es) | Inhibidores de quinasa de pirrolopirazina | |
AR070468A1 (es) | Pirrolopirazinas inhibidores de quinasa | |
CO6251243A2 (es) | Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c | |
PE20071001A1 (es) | Derivados de 1-(azolin-2-il)-amino-1-fenil-2-hetaril-etano con actividad pesticida | |
AR036095A1 (es) | Compuestos de pirazina que actuan como ligandos del receptor de 5-ht | |
AR105836A1 (es) | Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk | |
AR064279A1 (es) | Compuestos basados en la 4-fenil-6-(2,2,2-trifluoro-1- feniletoxi) pirimidina y metodos de uso de los mismos | |
AR080699A1 (es) | Pirrolopirazinas como inhibidores de jak y syk | |
AR059087A1 (es) | Derivados de pirimidina como inhibidores de pi-3 quinasa , uso de los mismos y composiciones farmaceuticas. | |
ES2540851T3 (es) | Compuesto de ciclopropano | |
AR081204A1 (es) | Pirrolopirazinas como inhibidores de quinasas | |
AR085607A1 (es) | Inhibidores de la mst1 quinasa y metodos para su utilizacion | |
CR9690A (es) | 3-acilaminobenzanilidas insecticidas | |
PE20141581A1 (es) | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante | |
RU2014122033A (ru) | Соединения с нематоцидной активностью | |
AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
PE20150767A1 (es) | Inhibidores de gdf-8 | |
AR078462A1 (es) | Inhibidores macrociclicos de la replicacion de virus de la hepatitis c | |
BRPI0721113A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para prevenir, tratar ou melhorar doenças ou condições dérmicas ou distúrbios | |
ES2778898T3 (es) | Compuestos inhibidores de la autotaxina | |
EA200970943A1 (ru) | Новое пиримидиновое соединение, имеющее структуру дибензиламина, и лекарственное средство, включающее данное соединение | |
MX2010006313A (es) | Inhibidores de la polimerasa virica. | |
AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
AR072803A1 (es) | Tetrahidrocinolinas como inhibidores de la 11- beta -hsd1 para la diabetes | |
AR076362A1 (es) | Arilsulfonamidas 2,5-disustituidas antagonistas de ccr3, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento y/o prevencion de patologias autoinmunes e inflamatorias, entre otras. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |